{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:30:33Z","timestamp":1795026633758,"version":"4.10.2"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Recent controversies have arisen regarding claims of uncritical positive regard and hype surrounding psychedelic drugs and their therapeutic potential. Criticisms have included that study designs and reporting styles bias positive over negative outcomes. The present study was motivated by a desire to address this alleged bias by intentionally focusing exclusively on negative outcomes, defined as self-perceived \u2018negative\u2019 psychological responses lasting for at least 72\u00a0h after psychedelic use. A strong justification for this selective focus was that it might improve our ability to capture otherwise missed cases of negative response, enabling us to validate their existence and better examine their nature, as well as possible causes, which could inspire risk-mitigation strategies. Via advertisements posted on social media, individuals were recruited who reported experiencing negative psychological responses to psychedelics (defined as classic psychedelics plus MDMA) lasting for greater than 72\u00a0h since using. Volunteers were directed to an online questionnaire requiring quantitative and qualitative input. A key second phase of this study involved reviewing all of the submitted cases, identifying the most severe\u2014e.g., where new psychiatric diagnoses were made or pre-existing symptoms made worse post psychedelic-use\u2014and inviting these individuals to participate in a semi-structured interview with two members of our research team, during which participant experiences and backgrounds were examined in greater depth. Based on the content of these interviews, a brief summary of each case was compiled, and an explorative thematic analysis was used to identify salient and consistent themes and infer common causes. 32 individuals fully completed an onboarding questionnaire (56% male, 53%\u2009&lt;\u2009age 25); 37.5% of completers had a psychiatric diagnosis that emerged\n                    <jats:italic>after<\/jats:italic>\n                    their psychedelic experience, and anxiety symptoms arose or worsened in 87%. Twenty of the seemingly severer cases were invited to be interviewed; of these, 15 accepted an in-depth interview that lasted on average 60\u00a0min. This sample was 40% male, mean age\u2009=\u200931\u2009\u00b1\u20097. Five of the 15 (i.e., 33%) reported receiving new psychiatric diagnoses after psychedelic-use and all fifteen reported the occurrence or worsening of psychiatric symptoms post use, with a predominance of anxiety symptoms (93%). Distilling the content of the interviews suggested the following potential causal factors: unsafe or complex environments during or surrounding the experience, unpleasant acute experiences (classic psychedelics), prior psychological vulnerabilities, high- or unknown drug quantities and young age. The current exploratory findings corroborate the reality of mental health iatrogenesis via psychedelic-use but due to design limitations and sample size, cannot be used to infer on its prevalence. Based on interview reports, we can infer a common, albeit multifaceted, causal mechanism, namely the combining of a pro-plasticity drug\u2014that was often \u2018over-dosed\u2019\u2014with adverse contextual conditions and\/or special psychological vulnerability\u2014either by young age or significant psychiatric history. Results should be interpreted with caution due to the small sample size and selective sample and study focus.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-41145-x","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:02:23Z","timestamp":1695621743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["Case analysis of long-term negative psychological responses to psychedelics"],"prefix":"10.1038","volume":"13","author":[{"given":"Rebecka","family":"Bremler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Katati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvinder","family":"Shergill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-6211","authenticated-orcid":false,"given":"David","family":"Erritzoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Carhart-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"issue":"7","key":"41145_CR1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"R Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R. et al. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry 3(7), 619\u2013627 (2016).","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"41145_CR2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. & Griffiths, R. R. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. 28(11), 983\u2013992 (2014).","journal-title":"J. Psychopharmacol."},{"key":"41145_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jad.2019.07.076","volume":"258","author":"S Muttoni","year":"2019","unstructured":"Muttoni, S., Ardissino, M. & John, C. Classical psychedelics for the treatment of depression and anxiety: A systematic review. J. Affect. Disord. 258, 11\u201324. https:\/\/doi.org\/10.1016\/j.jad.2019.07.076 (2019).","journal-title":"J. Affect. Disord."},{"key":"41145_CR4","volume-title":"How to Change Your Mind: What The New Science of Psychedelics Teaches us About Consciousness, Dying, Addiction, Depression, and Transcendence","author":"M Pollan","year":"2018","unstructured":"Pollan, M. How to Change Your Mind: What The New Science of Psychedelics Teaches us About Consciousness, Dying, Addiction, Depression, and Transcendence (Penguin, 2018)."},{"key":"41145_CR5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neulet.2016.07.004","volume":"649","author":"B Sessa","year":"2017","unstructured":"Sessa, B. MDMA and PTSD treatment: \u201dPTSD: From novel pathophysiology to innovative therapeutics\u201d. Neurosci. Lett. 649, 176\u2013180 (2017).","journal-title":"Neurosci. Lett."},{"key":"41145_CR6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1177\/0269881116679368","volume":"12","author":"JJ Rucker","year":"2016","unstructured":"Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D. & Young, A. H. Psychedelics in the treatment of unipolar mood disorders: A systematic review. J. Psychopharmacol. 12, 1220\u20131229. https:\/\/doi.org\/10.1177\/0269881116679368 (2016).","journal-title":"J. Psychopharmacol."},{"key":"41145_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12954-021-00489-1","volume":"18","author":"B Pilecki","year":"2021","unstructured":"Pilecki, B., Luoma, J. B., Bathje, G. J., Rhea, J. & Fraguada Narloch, V. Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduct. J. 18, 40. https:\/\/doi.org\/10.1186\/s12954-021-00489-1 (2021).","journal-title":"Harm Reduct. J."},{"key":"41145_CR8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108715","volume":"223","author":"B Killion","year":"2021","unstructured":"Killion, B. et al. LSD use in the United States: Trends, correlates, and a typology of us. Drug Alcohol Depend. 223, 108715 (2021).","journal-title":"Drug Alcohol Depend."},{"key":"41145_CR9","unstructured":"U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Centre for Behavioural Health Statistics and Quality. (2021). National Survey on Drug Use and Health 2021. Retrieved from: https:\/\/pdas.samhsa.gov\/#\/survey\/NSDUH-2021-DS0001"},{"key":"41145_CR10","doi-asserted-by":"crossref","first-page":"108071","DOI":"10.1016\/j.drugalcdep.2020.108071","volume":"212","author":"RA Yockey","year":"2020","unstructured":"Yockey, R. A., Vidourek, R. A. & King, K. A. Trends in LSD use among US adults: 2015\u20132018. Drug Alcohol Depend. 212, 108071 (2020).","journal-title":"Drug Alcohol Depend."},{"key":"41145_CR11","first-page":"234","volume":"2021","author":"H Kettner","year":"2021","unstructured":"Kettner, H. et al. Psychedelic communitas: Intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness. Front. Pharmacol. 2021, 234 (2021).","journal-title":"Front. Pharmacol."},{"issue":"8","key":"41145_CR12","doi-asserted-by":"crossref","first-page":"e63972","DOI":"10.1371\/journal.pone.0063972","volume":"8","author":"TS Krebs","year":"2013","unstructured":"Krebs, T. S. & Johansen, P. \u00d8. Psychedelics and mental health: A population study. PLoS ONE 8(8), e63972 (2013).","journal-title":"PLoS ONE"},{"key":"41145_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcbs.2019.11.001","volume":"15","author":"RJ Zeifman","year":"2020","unstructured":"Zeifman, R. J. & Wagner, A. C. Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder. J. Contextual Behav. Sci. 15, 1\u201311 (2020).","journal-title":"J. Contextual Behav. Sci."},{"issue":"8","key":"41145_CR14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/02698811221101061","volume":"36","author":"VA Nygart","year":"2022","unstructured":"Nygart, V. A. et al. Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. J. Psychopharmacol. 36(8), 932\u2013942. https:\/\/doi.org\/10.1177\/02698811221101061 (2022).","journal-title":"J. Psychopharmacol."},{"key":"41145_CR15","doi-asserted-by":"publisher","first-page":"647909","DOI":"10.3389\/fpsyt.2021.647909","volume":"12","author":"K Mans","year":"2021","unstructured":"Mans, K. et al. Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample. Front. Psychiatry. 12, 647909. https:\/\/doi.org\/10.3389\/fpsyt.2021.647909 (2021).","journal-title":"Front. Psychiatry."},{"issue":"7","key":"41145_CR16","doi-asserted-by":"crossref","first-page":"e25973","DOI":"10.2196\/25973","volume":"23","author":"S H\u00fcbner","year":"2021","unstructured":"H\u00fcbner, S., Haijen, E., Kaelen, M., Carhart-Harris, R. L. & Kettner, H. Turn on, tune in, and drop out: Predictors of attrition in a prospective observational cohort study on psychedelic use. J. Med. Internet Res. 23(7), e25973 (2021).","journal-title":"J. Med. Internet Res."},{"key":"41145_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/00048674221081763","author":"S Muthukumaraswamy","year":"2022","unstructured":"Muthukumaraswamy, S., Forsyth, A. & Sumner, R. L. The challenges ahead for psychedelic \u201cmedicine\u201d. Aust. N. Z. J. Psychiatry https:\/\/doi.org\/10.1177\/00048674221081763 (2022).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"41145_CR18","unstructured":"Kay Ross, Lily (Host). Power Trip (Season 1) [Audio podcast epis]. In Cover Story. New York Magazine. https:\/\/podcasts.apple.com\/us\/podcast\/cover-story\/id1594675355 (2021)."},{"issue":"3","key":"41145_CR19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187(3), 268\u2013283 (2006).","journal-title":"Psychopharmacology"},{"issue":"12","key":"41145_CR20","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881116678781","volume":"30","author":"FS Barrett","year":"2016","unstructured":"Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S., Johnson, M. W. & Griffiths, R. R. The challenging experience questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J. Psychopharmacol. 30(12), 1279\u20131295 (2016).","journal-title":"J. Psychopharmacol."},{"key":"41145_CR21","doi-asserted-by":"crossref","unstructured":"Johnstad, P. G. Day trip to hell: A mixed methods study of challenging psychedelic experiences. J. Psychedelic Stud. 5 (2), 114\u2013127. https:\/\/akjournals.com\/view\/journals\/2054\/5\/2\/article-p114.xml (2021).","DOI":"10.1556\/2054.2021.00155"},{"key":"41145_CR22","doi-asserted-by":"publisher","unstructured":"Gashi L, Sandberg S, Pedersen W. Making \"bad trips\" good: How users of psychedelics narratively transform challenging trips into valuable experiences. Int. J. Drug Policy. 87, 102997. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102997 (2021). (Epub 2020 Oct 17. Erratum in: Int J Drug Policy. 2021 Jul;93:103183).","DOI":"10.1016\/j.drugpo.2020.102997"},{"issue":"12","key":"41145_CR23","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro, T. M. et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J. Psychopharmacol. 30(12), 1268\u20131278 (2016).","journal-title":"J. Psychopharmacol."},{"issue":"9","key":"41145_CR24","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/0269881119855974","volume":"33","author":"L Roseman","year":"2019","unstructured":"Roseman, L. et al. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. J. Psychopharmacol. 33(9), 1076\u20131087 (2019).","journal-title":"J. Psychopharmacol."},{"key":"41145_CR25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3389\/fphar.2018.00897","volume":"2018","author":"EC Haijen","year":"2018","unstructured":"Haijen, E. C. et al. Predicting responses to psychedelics: A prospective study. Front. Pharmacol. 2018, 897 (2018).","journal-title":"Front. Pharmacol."},{"key":"41145_CR26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00005053-196001000-00005","volume":"130","author":"S Cohen","year":"1960","unstructured":"Cohen, S. Lysergic acid diethylamide: Side effects and complications. J. Nerv. Ment. Dis. 130, 30\u201340 (1960).","journal-title":"J. Nerv. Ment. Dis."},{"issue":"11","key":"41145_CR27","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"E Studerus","year":"2011","unstructured":"Studerus, E., Kometer, M., Hasler, F. & Vollenweider, F. X. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. J. Psychopharmacol. 25(11), 1434\u20131452 (2011).","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"41145_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaclp.2020.12.012","volume":"62","author":"NB Giancola","year":"2021","unstructured":"Giancola, N. B., Korson, C. J., Caplan, J. P. & McKnight, C. A. A \u201cTrip\u201d to the Intensive Care Unit: An Intravenous Injection of Psilocybin. J. Acad. Consult. Liaison Psychiatry. 62(3), 370\u2013371. https:\/\/doi.org\/10.1016\/j.jaclp.2020.12.012 (2021).","journal-title":"J. Acad. Consult. Liaison Psychiatry."},{"key":"41145_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00005053-196312000-00007","volume":"137","author":"T Leary","year":"1963","unstructured":"Leary, T., Litwin, G. H. & Metzner, R. Reactions to psilocybjn administered in a supportive environment. J. Nerv. Ment. Dis. 137, 561\u2013573. https:\/\/doi.org\/10.1097\/00005053-196312000-00007 (1963).","journal-title":"J. Nerv. Ment. Dis."},{"issue":"7","key":"41145_CR30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. L. et al. Psychedelics and the essential importance of context. J. Psychopharmacol. 32(7), 725\u2013731. https:\/\/doi.org\/10.1177\/0269881118754710 (2018).","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"41145_CR31","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn, I. Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. J. Psychopharmacol. 30(12), 1259\u20131267 (2016).","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"41145_CR32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/02791072.1997.10400190","volume":"29","author":"B Eisner","year":"1997","unstructured":"Eisner, B. Set, setting, and matrix. J. Psychoactive Drugs 29(2), 213\u2013216 (1997).","journal-title":"J. Psychoactive Drugs"},{"issue":"2","key":"41145_CR33","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","volume":"4","author":"JS Aday","year":"2021","unstructured":"Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K. & Davoli, C. C. Predicting reactions to psychedelic drugs: A systematic review of states and traits related to acute drug effects. ACS Pharmacol. Transl. Sci. 4(2), 424\u2013435 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"41145_CR34","unstructured":"Marrocu et al. Unknown title [Manuscript submitted for publication] Department of Brain Sciences, Imperial College London (2023)."},{"key":"41145_CR35","volume-title":"Living Outside Mental Illness","author":"L Davidson","year":"2003","unstructured":"Davidson, L. Living Outside Mental Illness (New York University Press, 2003)."},{"key":"41145_CR36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fpsyt.2017.00129","volume":"8","author":"W Lu","year":"2017","unstructured":"Lu, W., Mueser, K. T., Rosenberg, S. D., Yanos, P. T. & Mahmoud, N. Posttraumatic reactions to psychosis: A qualitative analysis. Front. Psych. 8, 129 (2017).","journal-title":"Front. Psych."},{"key":"41145_CR37","volume-title":"Acid Dreams: The Complete Social History of LSD: The CIA, The Sixties, and Beyond","author":"MA Lee","year":"1992","unstructured":"Lee, M. A. & Shlain, B. Acid Dreams: The Complete Social History of LSD: The CIA, The Sixties, and Beyond (Grove Press, 1992)."},{"key":"41145_CR38","volume-title":"Storming Heaven: LSD and The American Dream","author":"J Stevens","year":"1987","unstructured":"Stevens, J. Storming Heaven: LSD and The American Dream (Grove Press, 1987)."},{"issue":"1723","key":"41145_CR39","doi-asserted-by":"crossref","first-page":"20160141","DOI":"10.1098\/rstb.2016.0141","volume":"372","author":"R Altwegg","year":"2017","unstructured":"Altwegg, R., Visser, V., Bailey, L. D. & Erni, B. Learning from single extreme events. Philos. Trans. R. Soc. B: Biol. Sci. 372(1723), 20160141 (2017).","journal-title":"Philos. Trans. R. Soc. B: Biol. Sci."},{"key":"41145_CR40","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed) (Sage, 2013). https:\/\/doi.org\/10.1176\/appi.books.9780890425596.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"10","key":"41145_CR41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00005053-198410000-00001","volume":"172","author":"RJ Strassman","year":"1984","unstructured":"Strassman, R. J. Adverse reactions to psychedelic drugs. A review of the literature. J. Nerv. Ment. Dis. 172(10), 577\u2013595 (1984).","journal-title":"J. Nerv. Ment. Dis."},{"issue":"6","key":"41145_CR42","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1055\/s-2008-1038191.PMID:18512184","volume":"76","author":"L Hermle","year":"2008","unstructured":"Hermle, L., Kovar, K. A., Hewer, W. & Ruchsow, M. Hallucinogen-induced psychological disorders. Fortschr. Neurol. Psychiatr. 76(6), 334\u2013342. https:\/\/doi.org\/10.1055\/s-2008-1038191.PMID:18512184 (2008).","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"41145_CR43","volume-title":"Successful Qualitative Research: A Practical Guide For Beginners","author":"V Braun","year":"2013","unstructured":"Braun, V. & Clarke, V. Successful Qualitative Research: A Practical Guide For Beginners (Sage, 2013)."},{"key":"41145_CR44","unstructured":"Department of Health. Mental Capacity Act. (HMSO, 2005)."},{"issue":"3","key":"41145_CR45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0149-7634(03)00031-9","volume":"27","author":"JC Cole","year":"2003","unstructured":"Cole, J. C. & Sumnall, H. R. The pre-clinical behavioural pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA). Neurosci. Biobehav. Rev. 27(3), 199\u2013217 (2003).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"41145_CR46","doi-asserted-by":"publisher","unstructured":"Steinkellner, T., Freissmuth, M., Sitte, H. H., & Montgomery, T. The ugly side of amphetamines: Short-and long-term toxicity of 3, 4-methylenedioxymethamphetamine (MDMA,\u2018Ecstasy\u2019), methamphetamine and D-amphetamine.\nBiological Chemistry. https:\/\/doi.org\/10.1515\/bc.2011.016 (2011).","DOI":"10.1515\/bc.2011.016"},{"key":"41145_CR47","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0269881114565653","volume":"3","author":"PS Hendricks","year":"2015","unstructured":"Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W. & Johnson, M. W. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J. Psychopharmacol. 3, 280\u2013288. https:\/\/doi.org\/10.1177\/0269881114565653 (2015).","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"41145_CR48","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27(6), 1025\u20131033 (2021).","journal-title":"Nat. Med."},{"issue":"2","key":"41145_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00213-020-05719-1","volume":"238","author":"NL Galv\u00e3o-Coelho","year":"2021","unstructured":"Galv\u00e3o-Coelho, N. L. et al. Classic serotonergic psychedelics for mood and depressive symptoms: A meta-analysis of mood disorder patients and healthy participants. Psychopharmacol. Berl. 238(2), 341\u2013354. https:\/\/doi.org\/10.1007\/s00213-020-05719-1 (2021).","journal-title":"Psychopharmacol. Berl."},{"issue":"12","key":"41145_CR50","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1176\/appi.ajp.22010073","volume":"179","author":"G Barber","year":"2022","unstructured":"Barber, G., Nemeroff, C. B. & Siegel, S. A case of prolonged mania, psychosis, and severe depression after psilocybin use: Implications of increased psychedelic drug availability. Am. J. Psychiatry 179(12), 892\u2013896. https:\/\/doi.org\/10.1176\/appi.ajp.22010073 (2022).","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"41145_CR51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/14659890903271624","volume":"15","author":"RL Carhart-Harris","year":"2010","unstructured":"Carhart-Harris, R. L. & Nutt, D. J. User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. J. Substance Use 15(4), 283\u2013300 (2010).","journal-title":"J. Substance Use"},{"issue":"10","key":"41145_CR52","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1360-0443.1993.tb02018.x","volume":"88","author":"HD Abraham","year":"1993","unstructured":"Abraham, H. D. & Aldridge, A. M. Adverse consequences of lysergic acid diethylamide. Addiction 88(10), 1327\u20131334 (1993).","journal-title":"Addiction"},{"issue":"1","key":"41145_CR53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/15622970410029908","volume":"5","author":"RJ Nielen","year":"2004","unstructured":"Nielen, R. J., Heijden, F. M. V. D., Tuinier, S. & Verhoeven, W. M. Khat and mushrooms associated with psychosis. World J. Biol. Psychiatry 5(1), 49\u201353 (2004).","journal-title":"World J. Biol. Psychiatry"},{"issue":"3","key":"41145_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/brainsci8030047","volume":"8","author":"G Martinotti","year":"2018","unstructured":"Martinotti, G. et al. Hallucinogen persisting perception disorder: Etiology, clinical features, and therapeutic perspectives. Brain Sci. 8(3), 47. https:\/\/doi.org\/10.3390\/brainsci8030047 (2018).","journal-title":"Brain Sci."},{"issue":"4","key":"41145_CR55","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/0269881120959637","volume":"35","author":"A Brouwer","year":"2021","unstructured":"Brouwer, A. & Carhart-Harris, R. L. Pivotal mental states. J. Psychopharmacol. 35(4), 319\u2013352. https:\/\/doi.org\/10.1177\/0269881120959637 (2021).","journal-title":"J. Psychopharmacol."},{"key":"41145_CR56","first-page":"109398","volume":"2022","author":"RL Carhart-Harris","year":"2022","unstructured":"Carhart-Harris, R. L. et al. Canalization and plasticity in psychopathology. Neuropharmacology 2022, 109398 (2022).","journal-title":"Neuropharmacology"},{"issue":"4","key":"41145_CR57","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0749-3797(98)00017-8","volume":"14","author":"VJ Felitti","year":"1998","unstructured":"Felitti, V. J. et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: The Adverse Childhood Experiences (ACE) Study. Am. J. Prev. Med. 14(4), 245\u2013258 (1998).","journal-title":"Am. J. Prev. Med."},{"issue":"4","key":"41145_CR58","first-page":"427","volume":"63","author":"DL Stoewen","year":"2022","unstructured":"Stoewen, D. L. Nature, nurture, and mental health Part 1: The influence of genetics, psychology, and biology. Can. Vet. J. 63(4), 427\u2013430 (2022).","journal-title":"Can. Vet. J."},{"key":"41145_CR59","doi-asserted-by":"publisher","DOI":"10.31234\/osf.io\/txzha","author":"K Zhou","year":"2022","unstructured":"Zhou, K., De Wied, D., Carhart-Harris, R. & Kettner, H. Predictors of hallucinogen persisting perception disorder symptoms, delusional ideation and magical thinking following naturalistic psychedelic use. Mol. Psychiatry https:\/\/doi.org\/10.31234\/osf.io\/txzha (2022).","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"41145_CR60","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41380-021-01047-8","volume":"27","author":"JR Homberg","year":"2022","unstructured":"Homberg, J. R. & Jagiellowicz, J. A neural model of vulnerability and resilience to stress-related disorders linked to differential susceptibility. Mol. Psychiatry 27(1), 514\u2013524 (2022).","journal-title":"Mol. Psychiatry"},{"key":"41145_CR61","unstructured":"Grof, S. LSD: Doorway to the Numinous (Park Street Press, 1975 [Originally published as Realms of the Human Unconscious]) (1975)."},{"key":"41145_CR62","unstructured":"Kay Ross, L. (Host). Open Heart Surgery (No. 6) [Audio podcast episode]. In Cover Story. New York Magazine. https:\/\/podcasts.apple.com\/us\/podcast\/open-heart-surgery\/id1594675355?i=1000552567394 (2022)."},{"issue":"9\u201310","key":"41145_CR63","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1081\/JA-200066814","volume":"40","author":"K McElrath","year":"2005","unstructured":"McElrath, K. MDMA and sexual behavior: Ecstasy users\u2019 perceptions about sexuality and sexual risk. Subst. Use Misuse 40(9\u201310), 1461\u20131477 (2005).","journal-title":"Subst. Use Misuse"},{"key":"41145_CR64","first-page":"710","volume":"2021","author":"I Gorman","year":"2021","unstructured":"Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K. & Sabbagh, J. Psychedelic harm reduction and integration: A transtheoretical model for clinical practice. Front. Psychol. 2021, 710 (2021).","journal-title":"Front. Psychol."},{"key":"41145_CR65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0378-4274(99)00219-2","volume":"112","author":"P McGuire","year":"2000","unstructured":"McGuire, P. Long term psychiatric and cognitive effects of MDMA use. Toxicol. Lett. 112, 153\u2013156 (2000).","journal-title":"Toxicol. Lett."},{"key":"41145_CR66","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221084063","author":"EI Kopra","year":"2022","unstructured":"Kopra, E. I., Ferris, J. A., Winstock, A. R., Young, A. H. & Rucker, J. J. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. J. Psychopharmacol. https:\/\/doi.org\/10.1177\/02698811221084063 (2022).","journal-title":"J. Psychopharmacol."},{"key":"41145_CR67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.paid.2017.06.004","volume":"117","author":"FS Barrett","year":"2017","unstructured":"Barrett, F. S., Johnson, M. W. & Griffiths, R. R. Neuroticism is associated with challenging experiences with psilocybin mushrooms. Person. Individ. Differ. 117, 155\u2013160 (2017).","journal-title":"Person. Individ. Differ."},{"key":"41145_CR68","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson, M. W., Griffiths, R. R., Hendricks, P. S. & Henningfield, J. E. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142, 143\u2013166. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.012 (2018).","journal-title":"Neuropharmacology"},{"key":"41145_CR69","doi-asserted-by":"crossref","first-page":"109214","DOI":"10.1016\/j.neuropharm.2022.109214","volume":"2022","author":"SJ Belouin","year":"2022","unstructured":"Belouin, S. J. et al. Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. Neuropharmacology 2022, 109214 (2022).","journal-title":"Neuropharmacology"},{"issue":"3","key":"41145_CR70","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"AK Schlag","year":"2022","unstructured":"Schlag, A. K., Aday, J., Salam, I., Neill, J. C. & Nutt, D. J. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J. Psychopharmacol. 36(3), 258\u2013272. https:\/\/doi.org\/10.1177\/02698811211069100 (2022).","journal-title":"J. Psychopharmacol."},{"key":"41145_CR71","doi-asserted-by":"publisher","first-page":"788155","DOI":"10.3389\/fphar.2021.788155","volume":"12","author":"R Murphy","year":"2022","unstructured":"Murphy, R. et al. Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Front. Pharmacol. 12, 788155. https:\/\/doi.org\/10.3389\/fphar.2021.788155 (2022).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"41145_CR72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","volume":"78","author":"D Nutt","year":"2021","unstructured":"Nutt, D. & Carhart-Harris, R. The current status of psychedelics in psychiatry. JAMA Psychiat. 78(2), 121\u2013122 (2021).","journal-title":"JAMA Psychiat."},{"issue":"4","key":"41145_CR73","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths, R. R. et al. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacol. (Berl). 218(4), 649\u2013665. https:\/\/doi.org\/10.1007\/s00213-011-2358-5 (2011).","journal-title":"Psychopharmacol. (Berl)."},{"issue":"20","key":"41145_CR74","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310(20), 2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053 (2013).","journal-title":"JAMA"},{"key":"41145_CR75","first-page":"1","volume":"2016","author":"J Kuc","year":"2021","unstructured":"Kuc, J. et al. Psychedelic experience dose-dependently modulated by cannabis: Rresults of a prospective online survey. Psychopharmacology 2016, 1\u201316 (2021).","journal-title":"Psychopharmacology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41145-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T18:26:22Z","timestamp":1700331982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41145-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["41145"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-41145-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15998"}}